Patients with severe major depressive disorders, including chronic and severe anxiety states, severe bipolar, bipolar depression and postpartum depression would be ideal candidates for Ketamine infusion therapy when other forms of treatment such as medications, inpatient or outpatient therapy, ECT, TMS, etc., have failed to provide relief. In addition, patients with severe depression and who suffer from bouts of suicidal ideations, and who need immediate therapy, will benefit from Ketamine infusion therapy. In other words, patients who appear to suffer from treatment-resistant severe depression are probably ideal candidates for Ketamine infusion therapy.


50-60% of patients notice improvement after just one treatment


In sub-anesthetic doses, Ketamine has been used quite effectively in the management of treatment-resistant major depressive disorders, bipolar disorder, and as well in emergencies during periods of severe major depression with suicidal ideations. Ketamine has been available since the 1960s, but more recently is used in the management of treatment-resistant depressive disorders, and has been of considerable interest to mental healthcare professionals. Ketamine is provided to these patients in the form of an intravenous infusion at subanesthetic doses, it produces a fairly rapid and sustained response, and researchers believe that it works by blocking NMDA receptors for glutamate. The mechanism of action of Ketamine in treating depression therefore is different from other medications that are used in the treatment of these disorders.